Home  »  Business   »  Is Vera Therapeutics Inc. (NASDAQ: VERA) Expensive...

Is Vera Therapeutics Inc. (NASDAQ: VERA) Expensive At $7.13? Check These Facts.

Vera Therapeutics Inc. (NASDAQ:VERA)’s traded shares stood at 1.69 million during the last session. At the close of trading, the stock’s price was $7.13, to imply a decrease of -1.79% or -$0.13 in intraday trading. The VERA share’s 52-week high remains $24.98, putting it -250.35% down since that peak but still an impressive 27.07% since price per share fell to its 52-week low of $5.20. The company has a valuation of $312.86M, with an average of 0.56 million shares in intraday trading volume over the past 10 days and average of 847.62K shares over the past 3 months.

Analysts have given a consensus recommendation of an Overweight for Vera Therapeutics Inc. (VERA), translating to a mean rating of 2.30. Of 7 analyst(s) looking at the stock, 0 analyst(s) give VERA a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.9.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Vera Therapeutics Inc. (NASDAQ:VERA) trade information

After registering a -1.79% downside in the last session, Vera Therapeutics Inc. (VERA) has traded red over the past five days. The stock hit a weekly high of 7.73 this Friday, 03/17/23, dropping -1.79% in its intraday price action. The 5-day price performance for the stock is -3.26%, and -9.40% over 30 days. With these gigs, the year-to-date price performance is -63.15%. Short interest in Vera Therapeutics Inc. (NASDAQ:VERA) saw shorts transact 1.24 million shares and set a 1.22 days time to cover.

Analysts on Wall Street suggest a consensus price target of $19.17, implying an increase of 62.81% to the stock’s current value. The extremes give us $6.00 and $38.00 for target low and target high price respectively. As such, VERA has been trading -432.96% off suggested target high and 15.85% from its likely low.

Vera Therapeutics Inc. (VERA) estimates and forecasts

Looking at statistics comparing Vera Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Vera Therapeutics Inc. (VERA) shares are -66.64% down over the last 6 months, with its year-to-date growth rate lower than industry average at -25.51% against 9.60%. Revenue is forecast to shrink -13.90% this quarter before falling -22.50% for the next one.

VERA Dividends

Vera Therapeutics Inc. has its next earnings report out on August 10. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Vera Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Vera Therapeutics Inc. (NASDAQ:VERA)’s Major holders

Vera Therapeutics Inc. insiders hold 5.77% of total outstanding shares, with institutional holders owning 62.38% of the shares at 66.20% float percentage. In total, 62.38% institutions holds shares in the company, led by FMR, LLC. As of Sep 29, 2022, the company held over 4.06 million shares (or 14.67% of shares), all amounting to roughly $86.44 million.

The next major institution holding the largest number of shares is Sofinnova Investments, Inc. with 3.18 million shares, or about 11.50% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $67.8 million.

We also have Fidelity Advisor Biotechnology Fund and Fidelity Select Portfolios – Biotechnology as the top two Mutual Funds with the largest holdings of the Vera Therapeutics Inc. (VERA) shares. Going by data provided on Dec 30, 2022, Fidelity Advisor Biotechnology Fund holds roughly 0.98 million shares. This is just over 3.55% of the total shares, with a market valuation of $18.97 million. Data from the same date shows that the other fund manager holds a little less at 0.78 million, or 2.82% of the shares, all valued at about 13.02 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts